Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.

Drug Des Devel Ther · 2015 · PMC4524379 · PMID 26251572

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

markedly significantno p-value reported

Mean lesion area within the innominate artery Morphometric analysis of Movat’s pentachrome staining revealed a markedly significant reduction of atherosclerotic lesion size in the group receiving the combination of olmesartan medoxomil and amlodipine besylate after 25 weeks on the study diet.

also in 476 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.